Interventional Glaucoma

Latest News

First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111
First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111

August 26th 2025

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients

August 21st 2025

Cynthia Steel, PhD, MBA, appointed as Chief Scientific Officer of The Glaucoma Research Foundation
Cynthia Steel, PhD, MBA, appointed as Chief Scientific Officer of The Glaucoma Research Foundation

August 14th 2025

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

August 13th 2025

Active lifestyle is tied to reduced visual field decline in primary open angle glaucoma
Active lifestyle is tied to reduced visual field decline in primary open angle glaucoma

August 12th 2025

Video Series
Video Interviews
Podcasts
2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
EyePod: Transforming the MIGS pipeline into clinical practice
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.